ArticlePLoS neglected tropical diseases2019
Photodynamic therapy combined with antifungal drugs against chromoblastomycosis and the effect of ALA-PDT on Fonsecaea in vitro.
Article in PLoS neglected tropical diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 32 citations in OpenAlex.
- Successful treatment of 40-year chronic auricular cutaneous infection caused by multidrug-resistantMedical mycology case reports · 2026Article
- Updates on Chromoblastomycosis: Evolving Insights in Clinical Management and Therapeutic Strategies.Current fungal infection reports · 2026Article
- Chromoblastomycosis in Peru: a retrospective review of 13 cases.BMC infectious diseases · 2025Article
- Improving treatment of chromoblastomycosis: the potential of COP1T-HA and antimicrobial photodynamic therapy againstMycology · 2025Article
- Analysis of the effect of ALA-PDT on macrophages in footpad model of mice infected withOpen medicine (Warsaw, Poland) · 2025Article
- Chromoblastomycosis in French Guiana: Epidemiology and Practices, 1955-2023.Journal of fungi (Basel, Switzerland) · 2024Article
- Cutaneous Alternariosis in Immunosuppressed Patients Treated with Photodynamic Therapy and Oral Antifungals, a Synergistic Strategy.Pharmaceuticals (Basel, Switzerland) · 2024Article
- A Lethal Case of DisseminatedJournal of fungi (Basel, Switzerland) · 2023Article
- Photodynamic Therapy for the Treatment of Fungal Infections.Infection and drug resistance · 2022Review
- Combination therapy for an elderly patient with chromoblastomycosis caused byAnnals of translational medicine · 2022Article
- Molecular Characteristics of Regional Chromoblastomycosis in Guangdong, China: Epidemiological, Clinical, Antifungal Susceptibility, and Serum Cytokine Profiles of 45 Cases.Frontiers in cellular and infection microbiology · 2022Article
- Antimicrobial Photodynamic Therapy: Latest Developments with a Focus on Combinatory Strategies.Pharmaceutics · 2021Review
- Photosensitizers Mediated Photodynamic Inactivation against Fungi.Nanomaterials (Basel, Switzerland) · 2021Review
- Photodynamic Therapy Combined with Antibiotics or Antifungals against Microorganisms That Cause Skin and Soft Tissue Infections: A Planktonic and Biofilm Approach to Overcome Resistances.Pharmaceuticals (Basel, Switzerland) · 2021Review
- Chromoblastomycosis in an Endemic Area of Brazil: A Clinical-Epidemiological Analysis and a Worldwide Haplotype Network.Journal of fungi (Basel, Switzerland) · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChromoblastomycosis is a chronic skin and subcutaneous fungal infection caused by dematiaceous fungi and is associated with low cure and high relapse rates. In southern China, Fonsecaea monophora and Fonsecaea pedrosoi are the main causative agents. PRINCIPAL
findingsWe treated 5 refractory and complex cases of chromoblastomycosis with 5-aminolevulinic acid photodynamic therapy (ALA-PDT) combined with oral antifungal drugs. The lesions improved after 4 to 9 sessions of ALA-PDT treatment at an interval of one or two weeks, and in some cases, mycological testing results became negative. The isolates were assayed for susceptibility to antifungal drugs and ALA-PDT in vitro, revealing sensitivity to terbinafine, itraconazole and voriconazole, with ALA-PDT altering the cell wall and increasing reactive oxygen species production.
conclusionsThese results provide the basis for the development of a new therapeutic approach, and ALA-PDT combined with oral antifungal drugs constitutes a promising alternative method for the treatment of refractory and complex cases of chromoblastomycosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.